Literature DB >> 11425886

Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant.

G B Mackensen1, M Patel, H Sheng, C L Calvi, I Batinic-Haberle, B J Day, L P Liang, I Fridovich, J D Crapo, R D Pearlstein, D S Warner.   

Abstract

Reactive oxygen species contribute to ischemic brain injury. This study examined whether the porphyrin catalytic antioxidant manganese (III) meso-tetrakis (N-ethylpyridinium-2-yl)porphyrin (MnTE-2-PyP(5+)) reduces oxidative stress and improves outcome from experimental cerebral ischemia. Rats that were subjected to 90 min focal ischemia and 7 d recovery were given MnTE-2-PyP(5+) (or vehicle) intracerebroventricularly 60 min before ischemia, or 5 or 90 min or 6 or 12 hr after reperfusion. Biomarkers of brain oxidative stress were measured at 4 hr after postischemic treatment (5 min or 6 hr). MnTE-2-PyP(5+), given 60 min before ischemia, improved neurologic scores and reduced total infarct size by 70%. MnTE-2-PyP(5+), given 5 or 90 min after reperfusion, reduced infarct size by 70-77% and had no effect on temperature. MnTE-2-PyP(5+) treatment 6 hr after ischemia reduced total infarct volume by 54% (vehicle, 131 +/- 60 mm(3); MnTE-2-PyP(5+), 300 ng, 60 +/- 68 mm(3)). Protection was observed in both cortex and caudoputamen, and neurologic scores were improved. No MnTE-2-PyP(5+) effect was observed if it was given 12 hr after ischemia. MnTE-2-PyP(5+) prevented mitochondrial aconitase inactivation and reduced 8-hydroxy-2'-deoxyguanosine formation when it was given 5 min or 6 hr after ischemia. In mice, MnTE-2-PyP(5+) reduced infarct size and improved neurologic scores when it was given intravenously 5 min after ischemia. There was no effect of 150 or 300 ng of MnTE-2-PyP(5+) pretreatment on selective neuronal necrosis resulting from 10 min forebrain ischemia and 5 d recovery in rats. Administration of a metalloporphyrin catalytic antioxidant had marked neuroprotective effects against focal ischemic insults when it was given up to 6 hr after ischemia. This was associated with decreased postischemic superoxide-mediated oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425886      PMCID: PMC6762378     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  62 in total

1.  Mice overexpressing extracellular superoxide dismutase have increased resistance to global cerebral ischemia.

Authors:  H Sheng; M Kudo; G B Mackensen; R D Pearlstein; J D Crapo; D S Warner
Journal:  Exp Neurol       Date:  2000-06       Impact factor: 5.330

2.  Periischemic cerebral blood flow (CBF) does not explain beneficial effects of isoflurane on outcome from near-complete forebrain ischemia in rats.

Authors:  G B Mackensen; B Nellgârd; M Kudo; H Sheng; R D Pearlstein; D S Warner
Journal:  Anesthesiology       Date:  2000-10       Impact factor: 7.892

3.  Measurement and characterization of superoxide generation in microglial cells: evidence for an NADPH oxidase-dependent pathway.

Authors:  S Sankarapandi; J L Zweier; G Mukherjee; M T Quinn; D L Huso
Journal:  Arch Biochem Biophys       Date:  1998-05-15       Impact factor: 4.013

4.  Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein).

Authors:  J M McCord; I Fridovich
Journal:  J Biol Chem       Date:  1969-11-25       Impact factor: 5.157

5.  Catalysis of the disproportionation of superoxide by metalloporphyrins. III.

Authors:  R F Pasternack; A Banth; J M Pasternack; C S Johnson
Journal:  J Inorg Biochem       Date:  1981-11       Impact factor: 4.155

6.  Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug. Evidence for chronic encephalopathic processes following ischemia.

Authors:  C Coimbra; M Drake; F Boris-Möller; T Wieloch
Journal:  Stroke       Date:  1996-09       Impact factor: 7.914

7.  Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia.

Authors:  T Kondo; A G Reaume; T T Huang; E Carlson; K Murakami; S F Chen; E K Hoffman; R W Scott; C J Epstein; P H Chan
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

8.  Genotoxicity of ribo- and deoxyribonucleosides of 8-hydroxyguanine, 5-hydroxycytosine, and 2-hydroxyadenine: induction of SCE in human lymphocytes and mutagenicity in Salmonella typhimurium TA 100.

Authors:  K Arashidani; N Iwamoto-Tanaka; M Muraoka; H Kasai
Journal:  Mutat Res       Date:  1998-07-17       Impact factor: 2.433

9.  Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia.

Authors:  G Yang; P H Chan; J Chen; E Carlson; S F Chen; P Weinstein; C J Epstein; H Kamii
Journal:  Stroke       Date:  1994-01       Impact factor: 7.914

10.  Inactivation-reactivation of aconitase in Escherichia coli. A sensitive measure of superoxide radical.

Authors:  P R Gardner; I Fridovich
Journal:  J Biol Chem       Date:  1992-05-05       Impact factor: 5.157

View more
  53 in total

1.  Neuroprotection against superoxide anion radical by metallocorroles in cellular and murine models of optic neuropathy.

Authors:  Akiyasu Kanamori; Maria-Magdalena Catrinescu; Atif Mahammed; Zeev Gross; Leonard A Levin
Journal:  J Neurochem       Date:  2010-04-29       Impact factor: 5.372

2.  Mitochondrial aconitase knockdown attenuates paraquat-induced dopaminergic cell death via decreased cellular metabolism and release of iron and H₂O₂.

Authors:  David Cantu; Ruth E Fulton; Derek A Drechsel; Manisha Patel
Journal:  J Neurochem       Date:  2011-05-19       Impact factor: 5.372

3.  Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease.

Authors:  Li-Ping Liang; Jie Huang; Ruth Fulton; Jennifer N Pearson-Smith; Brian J Day; Manisha Patel
Journal:  Toxicol Appl Pharmacol       Date:  2017-04-08       Impact factor: 4.219

4.  Manganese(III) tetrakis(1-methyl-4-pyridyl) porphyrin, a superoxide dismutase mimetic, reduces disease severity in in vitro and in vivo models for dry-eye disease.

Authors:  Agnė Žiniauskaitė; Symantas Ragauskas; Anita K Ghosh; Rubina Thapa; Anne E Roessler; Peter Koulen; Giedrius Kalesnykas; Jenni J Hakkarainen; Simon Kaja
Journal:  Ocul Surf       Date:  2019-02-23       Impact factor: 5.033

Review 5.  Prolyl 4-hydroxylase activity-responsive transcription factors: from hydroxylation to gene expression and neuroprotection.

Authors:  Ambreena Siddiq; Leila R Aminova; Rajiv R Ratan
Journal:  Front Biosci       Date:  2008-01-01

Review 6.  Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress.

Authors:  Ambreena Siddiq; Leila R Aminova; Rajiv R Ratan
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

Review 7.  Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities.

Authors:  Ines Batinic-Haberle; Ivan Spasojevic; Hubert M Tse; Artak Tovmasyan; Zrinka Rajic; Daret K St Clair; Zeljko Vujaskovic; Mark W Dewhirst; Jon D Piganelli
Journal:  Amino Acids       Date:  2010-05-16       Impact factor: 3.520

Review 8.  Mitochondrial metals as a potential therapeutic target in neurodegeneration.

Authors:  A Grubman; A R White; J R Liddell
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

9.  The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia.

Authors:  Sunghee Cho; Eun-Mi Park; Maria Febbraio; Josef Anrather; Laibaik Park; Gianfranco Racchumi; Roy L Silverstein; Costantino Iadecola
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

10.  Lipophilicity is a critical parameter that dominates the efficacy of metalloporphyrins in blocking the development of morphine antinociceptive tolerance through peroxynitrite-mediated pathways.

Authors:  Ines Batinić-Haberle; Michael M Ndengele; Salvatore Cuzzocrea; Júlio S Rebouças; Ivan Spasojević; Daniela Salvemini
Journal:  Free Radic Biol Med       Date:  2008-10-17       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.